Inspire nct02644369
Nettetinvestigator-initiated Phase II trial (INSPIRE, NCT02644369). Quantification of ctDNA: • Illumina HiSeq2500 was used for whole exome sequencing (WES) of 70 pre-P tumor samples (mean coverage 121.5X) and matched germline controls from peripheral blood mononuclear cells (mean coverage 40.2X). Nettet27. nov. 2024 · Placement Surgery. Inspire is a sleep apnea treatment. The device sends a signal to the nerve that controls your tongue and upper airway to tighten them while …
Inspire nct02644369
Did you know?
Nettet29. des. 2024 · The single-center, investigator-initiated biomarker phase II clinical trial called Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE; NCT02644369) prospectively enrolled patients from March 21, 2016, to May 9, 2024, into 5 cohorts: squamous cell cancer of the head and neck, triple … Nettetnct02644369, inspire-001 Conditions Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma, Advanced Solid Tumors
Nettet3. aug. 2024 · We conducted a prospective phase II clinical trial to assess ctDNA in five distinct cohorts of patients with advanced solid tumors treated with pembrolizumab … Nettet29. okt. 2024 · 由Natera制造的NGS测定法在2期INSPIRE试验(NCT02644369)中证明了其有效性，该试验评估了派姆单抗(Keytruda)单药治疗70例晚期癌症患者。 研究人员使 …
Nettet12. aug. 2024 · Findings from the INSPIRE, a prospective phase II clinical trial to assess circulating tumour DNA ... (NCT02644369). They included patients in 5 parallel cohorts … Nettet26. aug. 2024 · One-hundred and six patients were accrued from 21 March 2016 to 9 May 2024 to a single-center, investigator-initiated phase II interventional clinical trial …
NettetEvaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA …
Nettet1. okt. 2024 · Methods. Pts with mixed solid tumors received single agent P (anti-PD-1) 200 mg IV Q3wks in the investigator-initiated phase II INSPIRE trial (NCT02644369). ctDNA was assayed at baseline (B) and start of cycle 3 (C3) using a pt-specific amplicon-based NGS assay (Signatera™).Samples were considered ctDNA positive if ≥ 2 of 16 … rogue fitness westbelt driveNettet20. mai 2024 · Methods: INSPIRE (NCT02644369) is a biomarker-driven study to comprehensively evaluate changes in genomic and immune landscapes in tumors and … our tesco shareviewNettet5. aug. 2024 · 因此，Pugh和Siu团队发起了一个名为INSPIRE的前瞻性2期临床研究（ NCT02644369），以评估ctDNA检测在预测抗PD-1抗体治疗效果方面的能力。 … rogue fitness veteran discountNettet26. feb. 2024 · Methods: INSPIRE (NCT02644369) is a biomarker-driven Princess Margaret Cancer Centre initiative to evaluate genomic and immunologic changes in … rogue fitness training maskNettet2. jun. 2024 · Methods: Plasma was obtained from pts receiving ICI in two clinical trials (MET4-IO, NCT03686202 and INSPIRE, NCT02644369) and from healthy controls … rogue fitness towerNettet26. mai 2024 · Methods: Pts with mixed solid tumors received single agent P (anti-PD-1) 200 mg IV Q3wks in the investigator-initiated phase II INSPIRE trial (NCT02644369). … rogue flat footNettet31. des. 2015 · Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) ... NCT02644369. Locations. Layout table for location information; … rogue fitness wooden handles